Skip to content

Study · Not a test of the peptide alone · 2002

7 results

Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.

Igarashi H, Ito T, Pradhan TK, Mantey SA, Hou W, Coy DH, Jensen RT

The Journal of pharmacology and experimental therapeutics1 Nov 2002Cited by 28 (Europe PMC)

PMID12388623 (opens in a new tab)DOI10.1124/jpet.102.038075 (opens in a new tab)PepBankPUB-12388623
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, the VIP pharmacophore for VPAC(2) showed significant species differences.

    In plain wordsIn lab tests, the parts of VIP that matter for binding to the VPAC(2) receptor differed between species.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSpecies differences in the VIP pharmacophore for VPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    We found significant species differences
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, human VPAC(2) in CHO cells differed significantly from native VPAC(2) in Sup T(1) cells and VPAC(2) in PANC1 cells.

    In plain wordsIn lab tests, the human receptor made in CHO cells differed from the natural receptor and from the one in PANC1 cells.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableHuman VPAC(2) in CHO cells versus native VPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    the human VPAC(2) (hVPAC(2)) expressed in Chinese hamster ovary (CHO) cells, which have been used in previous studies, differed significantly from the native hVPAC(2) in Sup T(1) cells and hVPAC(2) expressed in PANC1 cells.
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, binding affinities and potencies for VPAC(2) activation were in close agreement.

    In plain wordsIn lab tests, how tightly the analogs bound VPAC(2) matched how strongly they switched it on.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAgreement between binding affinity and potency at VPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    There was a close agreement between binding affinities and potencies for VPAC(2) activation.
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, Asp(3), Phe(6), Thr(7), Tyr(10), Arg(12), Tyr(22) and Leu(23) were the most important residues for high-affinity potency at VPAC(2).

    In plain wordsIn lab tests, seven named amino acids of VIP were the most important for binding the VPAC(2) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidues most important for VIP affinity at VPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The amino acids whose backbone or side chain orientations were most important for high affinity potency are Asp(3), Phe(6), Thr(7), Tyr(10), Arg(12), Tyr(22), and Leu(23)
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, the side chains of Ser(2), Asp(8), Asn(9), Gln(16), Val(19), Lys(20), Lys(21), Asn(24) and Ser(25) were not essential for VPAC(2).

    In plain wordsIn lab tests, nine named amino acids of VIP were not needed for tight binding to the VPAC(2) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidues not essential for VIP activity at VPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    whereas the side chains of Ser(2), Asp(8), Asn(9), Gln(16), Val(19), Lys(20), Lys(21), Asn(24), and Ser(25) are not essential.
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  6. 06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, the side chains of Thr(7), Tyr(10), Thr(11) and Tyr(22) were much more critical for high affinity at human VPAC(2) than at human VPAC(1).

    In plain wordsIn lab tests, four named amino acids of VIP mattered much more for the VPAC(2) receptor than for the VPAC(1) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidues more critical at hVPAC(2) than hVPAC(1)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Comparison of the VIP pharmacophore between hVPAC(1) and hVPAC(2) demonstrated that the side chains of Thr(7), Tyr(10), Thr(11), and Tyr(22) were much more critical for high affinity for the hVPAC(2) than the hVPAC(1).
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  7. 07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In scanning assays, the orientation of the Asn(24) side chain was more important for high affinity at human VPAC(1) than at VPAC(2).

    In plain wordsIn lab tests, one amino acid of VIP mattered more for the VPAC(1) receptor than for the VPAC(2) receptor.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableResidue more important at hVPAC(1) than hVPAC(2)
    Study

    human, ratn: not reported in source

    CHO, PANC1 and Sup T(1) cells with VPAC(2)
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In contrast, the orientation of the side chain of Asn(24) was more important for high affinity for the hVPAC(1).
    1 context sentence
    Summary · context
    In this study we investigated the VIP pharmacophore for VPAC(2) by using alanine and D-amino acid scanning.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.